{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nonsmall+Cell+Lung+Cancer%2C+Stage+IV&page=20", "query": { "condition": "Nonsmall Cell Lung Cancer, Stage IV", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 1119, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nonsmall+Cell+Lung+Cancer%2C+Stage+IV&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nonsmall+Cell+Lung+Cancer%2C+Stage+IV&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T10:21:32.215Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY3537982", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1264, "start_date": "2023-12-21", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 87, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119581" }, { "nct_id": "NCT00676507", "title": "Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Neoplasm", "Carcinoma Non-small Cell Lung Cancer Stage IIIA", "Carcinoma Non-small Cell Lung Cancer Stage IIIB", "Carcinoma Non-small Cell Lung Cancer Stage IV" ], "interventions": [ { "name": "Lucanix™", "type": "BIOLOGICAL" }, { "name": "Placebo Comparator", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "NovaRx Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 532, "start_date": "2008-07", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2015-05-08", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 53, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00676507" }, { "nct_id": "NCT00806819", "title": "Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Nintedanib (BIBF1120)", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "B12", "type": "DRUG" }, { "name": "dexamethasone (or corticosteroid equivalent)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 718, "start_date": "2008-12", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-02", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 40, "location_summary": "Downy, California • Fountain Valley, California • Fullerton, California + 37 more", "locations": [ { "city": "Downy", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Meriden", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00806819" }, { "nct_id": "NCT03225664", "title": "Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2018-02-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Houston, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03225664" }, { "nct_id": "NCT01279798", "title": "Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Lucanix® (belagenpumatucel-L)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NovaRx Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-01", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01279798" }, { "nct_id": "NCT04837716", "title": "Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2021-03-18", "completion_date": "2027-09-23", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04837716" }, { "nct_id": "NCT00874107", "title": "Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Imprime PGG® Injection", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 90, "start_date": "2009-06", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 3, "location_summary": "Fayetteville, Arkansas • Canton, Ohio • San Antonio, Texas", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Canton", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00874107" }, { "nct_id": "NCT02919449", "title": "Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "MV-NIS", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vyriad, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-08-03", "completion_date": "2018-01-19", "has_results": true, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02919449" }, { "nct_id": "NCT02352948", "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non - Small Cell Lung Cancer NSCLC" ], "interventions": [ { "name": "MEDI4736 (durvalumab)", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)", "type": "DRUG" }, { "name": "tremelimumab (anti-CTLA4)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 597, "start_date": "2015-01-13", "completion_date": "2023-08-30", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 33, "location_summary": "Chandler, Arizona • Anaheim, California • Duarte, California + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02352948" }, { "nct_id": "NCT03348904", "title": "Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-12-27", "completion_date": "2018-05-22", "has_results": true, "last_update_posted_date": "2019-06-13", "last_synced_at": "2026-10-24T10:21:32.215Z", "location_count": 2, "location_summary": "Anaheim, California • Wichita, Kansas", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03348904" } ] }